- Home
- FRSH vs GH Comparison
FRSH vs GH Comparison
Compare FRSH & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRSH
- GH
- Stock Information
- Founded
- FRSH 2010
- GH 2011
- Country
- FRSH United States
- GH United States
- Employees
- FRSH N/A
- GH N/A
- Industry
- FRSH EDP Services
- GH Medical Specialities
- Sector
- FRSH Technology
- GH Health Care
- Exchange
- FRSH Nasdaq
- GH Nasdaq
- Market Cap
- FRSH 4.1B
- GH 3.0B
- IPO Year
- FRSH 2021
- GH 2018
- Fundamental
- Price
- FRSH $11.16
- GH $25.08
- Analyst Decision
- FRSH Buy
- GH Strong Buy
- Analyst Count
- FRSH 13
- GH 17
- Target Price
- FRSH $18.69
- GH $39.31
- AVG Volume (30 Days)
- FRSH 1.9M
- GH 2.5M
- Earning Date
- FRSH 10-29-2024
- GH 11-04-2024
- Dividend Yield
- FRSH N/A
- GH N/A
- EPS Growth
- FRSH N/A
- GH N/A
- EPS
- FRSH N/A
- GH N/A
- Revenue
- FRSH $652,935,000.00
- GH $643,810,000.00
- Revenue This Year
- FRSH $21.46
- GH $27.01
- Revenue Next Year
- FRSH $17.04
- GH $18.30
- P/E Ratio
- FRSH N/A
- GH N/A
- Revenue Growth
- FRSH 19.87
- GH 26.20
- 52 Week Low
- FRSH $10.96
- GH $15.81
- 52 Week High
- FRSH $24.98
- GH $37.04
- Technical
- Relative Strength Index (RSI)
- FRSH 40.74
- GH 42.70
- Support Level
- FRSH $11.10
- GH $23.07
- Resistance Level
- FRSH $11.48
- GH $27.13
- Average True Range (ATR)
- FRSH 0.29
- GH 1.30
- MACD
- FRSH -0.01
- GH 0.20
- Stochastic Oscillator
- FRSH 11.89
- GH 49.51
About FRSH Freshworks Inc.
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.